ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SKYA / insiders
LUNG (38) KRMD (41) APYX (21) PYPD (41) ⌘ Pro Terminal β†’

SkyAI Inc. (SKYA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.93 -1.35% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.92

SkyAI Inc. (SKYA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ SELL / AVOID Cap $128.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SKYA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SKYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, SkyAI Inc. (NASDAQ: SKYA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.93 (-1.35% 1D, market cap $128.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SKYA ranks #411 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SKYA compare to LUNG and KRMD in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), SKYA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and KRMD (KORU Medical Systems Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $138.1M). Among the 5-stock peer group, SKYA leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SKYA?
β–Ό

Per SKYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737995), SkyAI Inc. generated $204.1K in revenue (-98.7% YoY), -$282.5M in net income, and -$11.0M in free cash flow against $269.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.92 (-0.43%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (43/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D
Cash (8)Whales (13)SEC (11)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
$5 Bull$3 Base$2 Bear
πŸ“¬ FREE SKYA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SKYA)Realized 20D OHLCV Swing Band: Β±11.3%
Deterministic 5-Pillar Attribution (43/100 Composite)
πŸ” WHY SKYA SCORES 43/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (Β±11.3% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 11.30 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
35
Grade E$2.61+8.4% Next Q
Q2 (-2Q)
38
Grade E$2.83+2.8% Next Q
Q3 (-1Q)
40
Grade D$2.91+0.7% Next Q
Current
43
Grade D-$2.93-6.7% Hist 90D Ξ±
Trajectory: E (35) β†’ D- (43)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SKYA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SKYA currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.00) and Max Pain ($3.08) forces dealer call-delta covering toward $4.63.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SKYAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSKYA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

SKYA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SKYA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SKYA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKYA)

  • βœ“Walkthrough of SKYA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SKYA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +60.11%⚑ TESTING RESISTANCE
2026-11-03O $2.93H $2.97L $2.93C $2.93VOL 1.22M
RES: $3.00SUP: $1.06SMA50: $2.00SMA200: $1.69
$4.18$3.30$2.41$1.52$0.63RES $3.00SUP $1.06$2.932026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SKYA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SKYA Butterfly Map β†’ + Track SKYA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -98.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SKYA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SKYA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SKYA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKYA)

Health Care Rank #411 of 1015 βš”οΈ LUNG vs SKYA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SKYA vs. LUNG, KRMD, APYX, PYPD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SkyAI Inc. (SKYA) ranks #411 by composite RQD confidence (43/100, grade D-) and #624 by equity capitalization ($128.4M). Within this direct 5-issuer industry benchmark cohort, SKYA leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. SKYA currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SKYA ACTIVE
SkyAI Inc.
D- 43/100 β€” -30.0% -35.0% -1.35% $128.4M Benchmark Subject
LUNG
Pulmonx Corporation
D- 38/100 β€” 74.2% -35.0% -14.14% $129.1M /lung-vs-skya β†’
KRMD
KORU Medical Systems Inc.
D- 41/100 β€” 62.3% -28.7% +2.01% $138.1M /krmd-vs-skya β†’
APYX
Apyx Medical Corporation
E 21/100 β€” 62.5% -28.9% 0.00% $109.5M /apyx-vs-skya β†’
PYPD
PolyPid Ltd.
D- 41/100 β€” β€” -35.0% +0.56% $109.5M /pypd-vs-skya β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001737995 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SkyAI Inc. (SKYA) reported GAAP revenue of $204.1K (-98.7% vs. FY2024 revenue of $15.6M , and -99.3% cumulative change since FY2023) , GAAP net income of -$282.5M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (-142.1% YoY). On the balance sheet, SKYA closed FY2025 with $269.1M in total assets against $0 in total debt (Altman Z-Score: 11.30, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $204.1K -$282.5M -$11.0M -$11.0M $269.1M β€”
FY2024 (FY) 2024-12-31 $15.6M -$9.3M -$4.4M -$4.5M $7.3M β€”
FY2023 (FY) 2023-12-31 $28.4M -$9.8M -$8.5M -$8.5M β€” β€”

3. SKYA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SKYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SkyAI Inc. (NASDAQ: SKYA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.93 (-1.35% 1D, market cap $128.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SKYA ranks #411 in composite RQD confidence.

How does SKYA compare to LUNG and KRMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SKYA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and KRMD (KORU Medical Systems Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $138.1M). Among the 5-stock peer group, SKYA leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SKYA?

Per SKYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737995), SkyAI Inc. generated $204.1K in revenue (-98.7% YoY), -$282.5M in net income, and -$11.0M in free cash flow against $269.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SKYA trading relative to its 50-day, 200-day, and 52-week technical levels?

SKYA last traded at $2.93 (-1.35% on volume of 1,019,502 shares), positioning the stock +46.50% above its 50-day simple moving average ($2.00) and +73.37% above its 200-day simple moving average ($1.69). Across its 52-week range of $0.91 to $4.41, SKYA sits at the 57.7% percentile with a 14-day RSI of 75.1 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±11.3% ($2.60 to $3.26).

Direct Sub-Reports: SKYA RQD Cockpit SKYA 12M Forecast SKYA Earnings & Move SKYA Dividends & DRIP SKYA Insiders & 13F SKYA Whale Options SKYA Profit Sankey SKYA News & Why
ROARABLE RATING BRIEF β€’ RQD 43/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

SKYA β€” SkyAI Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SkyAI Inc. (SKYA) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.93 (-1.35% 1D, market capitalization $128.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of -8.67%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 11.30, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

And profile, SkyAI Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. The profile identifies its market capitalization as $0.1B. Reported FY 2025 revenue was $0.2M, indicating minimal commercial scale in the period.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SkyAI Inc. (SKYA) reported $204.1K in annual revenue (up from $15.6M in FY2024, -98.7% YoY) and -$282.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.4M revenue, -$9.8M net income) through FY2025, SKYA scaled operating cash flow to -$11.0M and free cash flow to -$11.0M, backed by $269.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.67% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $0.91 – $4.41 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are β€” Sector correlations beyond the Health Care sector classification are β€” Second-order bottlenecks cannot be identified from the supplied data.

  • Key Question #1: Can SKYA sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $204.1K and free cash flow of -$11.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SKYA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SKYA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SkyAI Inc. (SKYA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SKYA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SKYA Bull vs. Bear Conversation Board β€” What's Your Call at $2.93?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SKYA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SKYA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $3.42 (+15.2%)
πŸ“Œ Pinned Debate

A $201 million cash tender offer at $3 per share is reported, with the stock trading at $2.93 and institutional flow scoring 12 of 20.

A $201 million cash tender offer at $3 per share is reported, with the stock trading at $2.93 and institutional flow scoring 12 of 20.. When you look under the hood at SKYA, Fundamental Cash Engine is 8/20 with -30.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (13/20) has been quietly accumulating below $4.41. My 12M target is $3.42.

EarningsSniper πŸ‚ BULL

@FadeTheHype Shorting a 13/20 institutional whale-flow stock at $2.97 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.23 (-24.9%)
Spot @ $2.97

ROIC of -35%, FCF yield of -8.67%, and FY 2025 net loss of -$282.5M against $0.2M revenue leave no earnings anchor for valuation.

Here is the bear case nobody on the bull side wants to address on SKYA: ROIC of -35%, FCF yield of -8.67%, and FY 2025 net loss of -$282.5M against $0.2M revenue leave no earnings anchor for valuation.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE